Journavx is the first and only approved non-opioid oral painkiller and the first new class of pain medicine approved in more than 20 years.

A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug Administration (FDA).

Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.

The drug, shown to be almost as effective as opioids for short-term pain, is the first fundamentally new kind of painkiller to win FDA approval in more than 20 years.

Vertex Pharmaceuticals could soon capture $10 billion in sales of non-opioid painkillers, an analyst said Friday as Vertex stock jumped.

The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' drug to treat acute pain, the health regulator said on Thursday, offering a first-of-its-kind alternative to addictive opioid painkillers that have fueled a national crisis.

On Wednesday, the U.S. Food and Drug Administration approved a new pain management drug which could change the way healthcare providers address pain management. Suzetrigine, also known as Journavx, is classified within a new category of pain management medication without the same addictive qualities seen in many of its opiate competitors.